In this study we used GeneOptimizer technology to reengineer
human sRAGE cDNA. The optimization led to a higher level of
expression of a fully-active recombinant human sRAGE in CHO
cells. Assessment of critical parameters that impact autologous
sRAGE expression provides a technical information for future
large-scale production of this therapeutic protein for clinical trials
and medical needs